Fine Foods & Pharmaceuticals Ntm

AGM Information • May 8, 2024

Role

Company

Name Surname Fine Foods & Pharmaceuticals N.T.M. S.p.A. Filing and publication of lists for the Board of Directors and Board of Statutory Auditors appointments

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur Verdellino (Bergamo, Italy), 08 May 2024 - Fine Foods & Pharmaceuticals N.T.M. S.p.A., an Italian independent Contract Development & Manufacturing Organisation (CDMO), listed on Euronext STAR Milan (ticker: FF) - that develops and manufactures contract products for the pharmaceutical, nutraceutical, cosmetics industry ("Fine Foods" or the "Company"), announces that four lists of candidates for the appointments of the Company's Board of Directors and Board of Statutory Auditors, provided for respectively in the fifth and sixth items on the agenda of the Ordinary Shareholders' Meeting convened for 29 May 2024 on a single call, have been filed within the legal deadline and under the Company's Articles of Association (4 May 2024).

magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi For the Board of Directors appointment

• ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat (i) List 1 submitted by the majority shareholder Eigenfin S.r.l., holding 9,303,040 ordinary shares (and 3,500,000 multiple-voting shares), equal to 42.17% of the Company's listed share capital.
• estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, 1. Marco Francesco Eigenmann
• simus. 2. Giorgio Ferraris
• Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? 3. Marco Costaguta
• Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin 4. Giovanni Eigenmann
• cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea 5. Adriano Pala Ciurlo
• archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo 6. Ada Imperadore
• offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus 7. Susanna Pedretti
• plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. 8. Deborah Maria Venturini
• Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same 9. Elena Sacco
• nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma 10. Chiara Medioli Fedrigoni
• conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro (ii) List 2 submitted by INARCASSA, on behalf of shareholders Cassa Nazionale di Previdenza e Assistenza Forense and FONDOPOSTE, holding 1,454,233 shares, equal to 5.689% of the Company's share capital.
• velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia 1. Alessandra Piccinino
• con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil 2. Fabio Tomassini
• id moluptatur. 3. Fulvia Astolfi
• endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis (iii) List 3 submitted by a group of funds and institutional investors holding 777,000 shares, equal to 3.52219% of the Company's share capital.
• dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit 1. Daniele De Giovanni
• harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. 2. Stefania Caprara
• (iv) List 4 submitted by three minority shareholders: Enerfin S.r.l., Lwy. Francesco Gianni and Eng. Paolo Ferrario/ Augent Partners S.r.l. holding 721,293 shares, equal to 2.82% of the Company's share capital.
  • 1. Ferrario Paolo

Name Surname For the Board of Statutory Auditors appointment

Role Company (i) List 1 submitted by the majority shareholder Eigenfin S.r.l., holding 9,303,040 ordinary shares (and 3,500,000 multiple-voting shares), equal to 42.17% of the Company's listed share capital.

Statutory Auditors

• Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil 1. Massimo Pretelli
• eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il 2. Ottavia Alfano
• invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. 3. Maurizio Morosi

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Alternate Auditors

• maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore 1. Marco Antonio Manzoni
• solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a 2. Marco Dagrada
• dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi (ii) List 2submitted by INARCASSA, on behalf of shareholders Cassa Nazionale di Previdenza e Assistenza Forense and FONDOPOSTE, holding 1,454,233 shares, equal to 5.689% of the Company's share capital.

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Statutory Auditors

estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat 1. Paolo Russo

estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Alternate Auditors

• simus. 1. Stefania Mancino
• Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin (iii) List 3 submitted by a group of funds and institutional investors holding 777,000 shares, equal to 3.52219% of the Company's share capital.

cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Statutory Auditors

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo 1. Cecilia Andreoli

offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet Alternate Auditors

• haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. 1. Cesare Beolchi
• Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea (iv) List 4 submitted by three minority shareholders: Enerfin S.r.l., Lwy. Francesco Gianni and Eng. Paolo Ferrario/ Augent Partners S.r.l. holding 721,293 shares, equal to 2.82% of the Company's share capital.

iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea Statutory Auditors

vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro 1. Guido Croci

velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil Alternate Auditors

id moluptatur. 1. Marco Giuliani

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime The shareholder Eigenfin S.r.l.,

• eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. − when filing List 1 for the appointment of the Board of Directors – based on the guidelines provided by the Company's Board of Directors in the explanatory report of the above Shareholders' Meeting under item 5 of the Agenda - submitted resolution proposals for the following:
  • (i) item 5.1 "setting the number of Board of Directors members;"
  • (ii) item 5.2 "deciding the Board of Directors duration;"
  • (iii) item 5.4 "appointing the Board of Directors Chairperson;" and
  • (iv) item 5.5 "establishing the Board of Directors members' remuneration";

• Name Surname Role Company − when filing List 1 for the appointment of the Board of Statutory Auditors - based on the guidelines provided by the Company's Board of Directors in the explanatory report of the above Shareholders' Meeting under point 6 of the Agenda - submitted resolution proposals for the following:
  • (i) item 6.3 "establishing the Board of Statutory Auditors members' remuneration."

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. The above lists and mandatory documentation including candidates' résumés and the above proposed resolutions, were made available to the public today, within the legal terms, at the registered office, and the authorised storage system (available at ) and on the Fine Foods website www.finefoods.it(Governance section).

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.

dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi *** *** ***

solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent CDMO (Contract Development and Manufacturing Organisation). It develops and manufactures contract products for the pharmaceutical, nutraceutical and cosmetics industries. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, longterm partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. With € 251.8 million revenue in 2023, Fine Foods is a growing and future-oriented company.

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil

eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime

offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma For further information: Fine Foods & Pharmaceuticals N.T.M. S.p.A. Tel +39 035 4821382 Investor Relations: ir@finefoods.it Media Relations: media.relations@finefoods.it

id moluptatur.